Thera-SAbDab

PORGAVIXIMAB

>   Structural Summary
TherapeuticPorgaviximab
TargetZaire Ebolavirus GP
Heavy ChainEVQLQESGGGLMQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVKGRFTISRDDSKRSVYLQMNTLRAEDTGIYYCTRGNGNYRAMDYWGQGTSVTVSS
Light ChainDIQMTQSPASLSVSVGETVSITCRASENIYSSLAWYQQKQGKSPQLLVYSATILADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPYTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv Structure5kel [Fvs: HL, PT, QU]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Porgaviximab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 52B 52C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 101 102 103 104 105 106 107 108 109 110 111 112 113
porgaviximab E V Q L Q E S G G G L M Q P G G S M K L S C V A S G F T F S N Y W M N W V R Q S P E K G L E W V A E I R L K S N N Y A T H Y A E S V K G R F T I S R D D S K R S V Y L Q M N T L R A E D T G I Y Y C T R G N G N Y R A M D Y W G Q G T S V T V S S
5kel E V Q L Q E S G G G L M Q P G G S M K L S C V A S G F T F S N Y W M N W V R Q S P E K G L E W V A E I R L K S N N Y A T H Y A E S V K G R F T I S R D D S K R S V Y L Q M N T L R A E D T G I Y Y C T R G N G N Y R A M D Y W G Q G T S V T V S -

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
porgaviximab D I Q M T Q S P A S L S V S V G E T V S I T C R A S E N I Y S S L A W Y Q Q K Q G K S P Q L L V Y S A T I L A D G V P S R F S G S G S G T Q Y S L K I N S L Q S E D F G T Y Y C Q H F W G T P Y T F G G G T K L E I K
5kel D I Q M T Q S P A S L S V S V G E T V S I T C R A S E N I Y S S L A W Y Q Q K Q G K S P Q L L V Y S A T I L A D G V P S R F S G S G S G T Q Y S L K I N S L Q S E D F G T Y Y C Q H F W G T P Y T F G G G T K L E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (January '23)Phase-II
Estimated Status (January '23)Discontinued
Recorded Developmental TechnologyZmapp Technology
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedMapp Biopharmaceutical, Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedEbola virus infections
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy